AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

96,100

Employees96,100

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1913

Founded1913

Employees

96,100

Employees96,100

AZN Key Statistics

Market cap

323.50B

Market cap323.50B

Price-Earnings ratio

31.60

Price-Earnings ratio31.60

Dividend yield

1.52%

Dividend yield1.52%

Average volume

2.02M

Average volume2.02M

High today

$209.93

High today$209.93

Low today

$206.46

Low today$206.46

Open price

$207.47

Open price$207.47

Volume

1.81M

Volume1.81M

52 Week high

$212.71

52 Week high$212.71

52 Week low

$122.48

52 Week low$122.48

Stock Snapshot

With a market cap of 323.5B, AstraZeneca(AZN) trades at $208.40. The stock has a price-to-earnings ratio of 31.60 and currently yields dividends of 1.5%.

On 2026-03-01, AstraZeneca(AZN) stock moved within a range of $206.46 to $209.93. With shares now at $208.40, the stock is trading +0.9% above its intraday low and -0.7% below the session's peak.

Trading volume for AstraZeneca(AZN) stock has reached 1.81M, versus its average volume of 2.02M.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

AZN News

TipRanks 2d

AIRSUPRA vs. Albuterol: Completed Phase 4 Asthma Study Sets Up Next Catalyst for AstraZeneca

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The phase 4 study “A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the E...

Nasdaq 3d

AstraZeneca Prices $2 Bln Three Tranche Bond Offering

(RTTNews) - AstraZeneca PLC (AZN, AZN.L), a Swedish-British pharmaceutical and biotechnology company, on Thursday priced a three-tranche bond offering totalling...

TipRanks 4d

AstraZeneca Advances Subcutaneous Durvalumab Study, Targeting More Convenient Cancer Care

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca Starts New Study on Easier Cancer Immunotherapy Delivery. The Phase I...

Analyst ratings

81%

of 31 ratings

Buy

80.6%

Hold

9.7%

Sell

9.7%

More AZN News

TipRanks 5d

AstraZeneca’s CLARITY-Gastric 02 Trial Targets New Front in Stomach Cancer

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The CLARITY-Gastric 02 Phase 3 trial, led by AstraZeneca (GB:AZN), tests new drug...

Reuters 5d

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025 - Reuters

...

TipRanks 6d

AstraZeneca Taps Patient Insight to Bolster Capivasertib Breast Cancer Strategy

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study, titled “A Non-interventional, Observational Qualitative Interview Study of...

TipRanks 6d

AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab

AIM ImmunoTech (AIM) announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen combined with AstraZene...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.